AB-Therapeutics to participate at the annual meeting of the American Association of Cancer Research (AACR) in Chicago (USA)

Press Release

AB-Therapeutics to participate at the annual meeting of the American Association of Cancer Research (AACR) in Chicago (USA)

During the congress the company will present the first data with the compound ABTL0812, on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas.
The work presented has been selected by the evaluation committee of the AACR.

March 12, 2012

AB-Therapeutics, SL, pharmaceutical biotechnology company with a product in clinical phase planned for the third quarter of 2012, announced today that Jose Alfon, PhD, Director of Development, will participate in the Annual Meeting of the American Association of Cancer Research (AACR ) in Chicago from March 31 to April 4. Dr. Alfon will present the first data on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas with the compound ABTL0812. The work presented has been selected by the evaluation committee of the AACR.

ABTL0812 presents significant advantages over conventional chemotherapy: very low toxicity, oral administration, and most importantly, high efficacy. The product affects two cellular processes related to cell division and thus the proliferation of cancer cells: a) synthesis of DNA through inhibition of the expression of the dihydrofolate reductase (DHFR) gene, and b) inhibiting mTOR pathway that is involved in protein synthesis. By blocking these two key cellular functions, tumor cells are killed by a mechanism called autophagy, in which cells digest themselves.

About AB-Therapeutics, SL

AB-Therapeutics, SL is a research and development biopharmaceutical company founded in 2009 with headquarters in Bellaterra (Barcelona), Catalonia, Spain, located at the campus of the Autonomous University of Barcelona and with facilities planned in Boston in the US for 2012 .
AB-Therapeutics, SL aims to develop safer human therapies, based on the modulation of the activity of cell-membranes to treat various cancers, especially those with high medical needs due to its high mortality. The firm has a molecule, ABTL0812, in regulatory preclinical development, Phase I clinical trials (First in Man) is planned for the third quarter of 2012. A second drug candidate, ABTL1014 will begin preclinical development during the last quarter of 2012.

Contact:

Press:
Nuria Peláez
Tel +34 902 903 844
media.relations@ab-therapeutics.com
www.ab-therapeutics.com

Investors:
Carles Domenech, PhD
Tel +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com